(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2011 (10.02.2011)

PCT

(10) International Publication Number
WO 2011/014973 A2

(51) International Patent Classification:
C07D 498/04 (2006.01) *A61K 31/695* (2006.01)
C07D 498/18 (2006.01) *A61P 1/06* (2006.01)
C07F 7/08 (2006.01) *A61P 25/24* (2006.01)
A61K 31/4745 (2006.01)

(21) International Application Number:
PCT/CH2010/000191

(22) International Filing Date:
3 August 2010 (03.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2009/060168 5 August 2009 (05.08.2009) EP

(71) Applicant *(for all designated States except US)*: **POLYPHOR AG** [CH/CH]; Hegenheimermattweg 125, CH-4123 Allschwil (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OBRECHT, Daniel** [CH/CH]; Im Eichacker 21, CH-4112 Bättwil (CH). **ERMERT, Philipp** [CH/DE]; Steinbühlweg 31, CH-4123 Allschwil (CH). **OUMOUCH, Said** [FR/FR]; 39, rue du Soleil, F-68200 Mulhouse (FR). **LACH, Franck** [FR/FR]; 21, rue Principale, F-51400 Les Grandes Loges (FR). **LUTHER, Anatol** [DE/DE]; Max-Brombacher-Weg 10, 79589 Binzen (DE). **MARX, Karsten** [CH/DE]; Birkenstrasse 44, CH-4055 Basel (CH). **MÖHLE, Kerstin** [CH/DE]; Oberhausenstrasse 23, CH-8907 Wettswil (CH).

(74) Agent: **BRAUN, André**; Braunpat Braun Eder AG, Reussstrasse 22, CH-4054 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2011/014973 A2

(54) **Title**: CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS



Ia



Ib

(57) **Abstract**: Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors $P2Y_1$, as modulators of the serotonin receptor of subtype $5\text{-}HT_{2B}$, as blockers of the voltage-gated potassium channel $K_v1.3$ and as inhibitors of the β-catenin-dependent "canonical" Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.